MATAWAN, NJ--(Marketwire - Nov 6, 2012) -  PacificHealth Laboratories, Inc. (OTCQB: PHLI) (OTCBB: PHLI), a leading sports nutrition company, today reported its financial results for the quarter and nine months ended September 30, 2012.

Third Quarter & Nine Months 2012 vs. 2011 Financial Results

Revenues were $1,721,119 for the third quarter and $5,701,292 for the nine months ended September 30, 2012 compared to $1,971,624 and $5,948,461, respectively, for the same periods in 2011. Net loss for the third quarter of 2012 was ($345,439), or ($0.02) per share, and net loss was ($454,965), or ($0.02) per share, for the nine months ended September 30, 2012 compared to a net loss of ($116,675), or ($0.01) per share for the third quarter of 2011 and net income of $2,324, or $0.00 per diluted share, for the nine months ended September 30, 2011. Gross margins decreased primarily as a result of across the board raw material price increases, most notably higher protein costs. General and administrative expenses increased $37,842 in the third quarter and increased $161,865 for the nine months ended September 30, 2012 compared to the same periods in 2011 primarily as a result of the Company's investment in internet and social marketing expenses in 2012 of approximately $49,000 for the quarter and $206,000 for the first nine months.

At September 30, 2012, the Company had cash, cash equivalents, and other short-term investments of $324,477 compared to $820,904 at December 31, 2011. Current assets exceeded current liabilities by approximately $676,000 at September 30, 2012.

Fred Duffner, President and CEO of PacificHealth Laboratories, said, "The biggest impact to revenue in the third quarter was the transitioning from our old formula ACCELERADE and ENDUROX R4 to our new all-natural formulas. Our largest bicycle customer that transitioned over to all-natural in June had to manage through the sell-through of the old formula in the third quarter which negatively impacted purchases from us. In addition, we invested in markdown monies in support of the sell-through of the old formula with them and other major customers. This coupled with the reduction in inventory purchases by our nutritional channel customers has impacted our year to date revenues."

Mr. Duffner added, "We have completed the transition over to new all-natural formulas and new labeling in the marketplace as one of our key initiatives for 2012. We brought the management of our social and web-based marketing in-house as of the end of the third quarter which should reduce our G & A expenses moving forward. We also launched Body Glove Surge in August into Southern California as another of our key initiatives for 2012." 

Mr. Duffner concluded, "Although revenue results are below expectations we have completed the key initiatives to support our base business and launched Body Glove Surge which we believe provides us the opportunity to expand PHLI beyond its current channels and into broader distribution moving forward into 2013." 

About PacificHealth Laboratories, Inc.

PacificHealth Laboratories, Inc. (OTCQB: PHLI) (OTCBB: PHLI), founded in 1996 by two prominent scientists, started with a singular purpose -- to help athletes achieve their personal goals. We never lost sight of that mission. Collaborating with some of the world's top nutritionists, biochemists and sports scientists, our research and products have reshaped sports nutrition. Our discoveries help muscles work stronger, faster and longer and are an integral part of the daily training and race regimens of athletes at all levels. However, we are most proud of the simple fact that our products "power your passion." To learn more, visit www.pacifichealthlabs.com.

Notice: This news release and oral statements made from time to time by Company representatives concerning the same subject matter may contain so-called "forward-looking statements". These statements can be identified by introductory words such as "expects," "plans," "will," "estimates," "forecasts," "projects," or words of similar meaning and by the fact they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing new products and their potential. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known, such general economic conditions, consumer product acceptance and competitive products, and others of which are not. No forward-looking statements are a guarantee of future results or events, and one should avoid placing undue reliance on such statements.

SELECTED FINANCIAL DATA:

PACIFICHEALTH LABORATORIES, INC.
STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2012 AND 2011
(UNAUDITED)
		Three Months								Nine Months
		Ended September 30,								Ended September 30,
		2012				2011				2012				2011
Revenues:
	Net product sales	$	1,721,119			$	1,971,624			$	5,701,292			$	5,948,461
Cost of goods sold			1,136,016				1,120,865				3,505,914				3,332,367
Gross profit			585,103				850,759				2,195,378				2,616,094
Operating expenses:
	Sales and marketing		339,098				414,453				842,523				983,496
	General and administrative (Includes related party consulting of $48,189, $48,000, $146,809, $139,000, respectively)		567,427				529,585				1,739,924				1,578,059
	Research and development		16,458				16,141				51,945				40,936
			922,983				960,179				2,634,392				2,602,491
(Loss) income before other expense andprovision for income taxes			(337,880	)			(109,420	)			(439,014	)			13,603
Other (expense) income:
	Other income		-				-				-				2,100
	Interest income		125				112				359				391
	Interest expense		(7,684	)			(7,367	)			(16,310	)			(13,770	)
			(7,559	)			(7,255	)			(15,951	)			(11,279	)
(Loss) income before provision for income taxes			(345,439	)			(116,675	)			(454,965	)			2,324
Provision for income taxes			-				-				-				-
Net (loss) income		$	(345,439	)		$	(116,675	)		$	(454,965	)		$	2,324
Basic (loss) income per share		$	(0.02	)		$	(0.01	)		$	(0.02	)		$	0.00
Diluted (loss) income per share		$	(0.00	)		$	(0.00	)		$	(0.00	)		$	0.00
Weighted average common shares - basic			20,871,772				20,865,257				20,871,772				19,100,056
Weighted average common shares - diluted			20,871,772				20,865,257				20,871,772				19,330,073

PACIFICHEALTH LABORATORIES, INC.
BALANCE SHEETS
(UNAUDITED)
ASSETS
				September 30,				December 31,
				2012				2011
Current assets:
	Cash and cash equivalents			$	274,477			$	745,904
	Other short-term investments				50,000				75,000
	Accounts receivable, net				676,572				369,376
	Inventories, net				746,104				571,403
	Prepaid expenses				93,968				91,479
		Total current assets			1,841,121				1,853,162
Property and equipment, net					140,182				26,729
Deposits					10,895				10,895
			Total assets	$	1,992,198			$	1,890,786
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
	Line of credit			$	25,000			$	37,500
	Notes payable				29,864				19,679
	Accounts payable and accrued expenses (Includes relatedparty of $16,000 and $32,000, respectively)				1,059,183				546,712
	Deferred revenue				51,024				56,170
		Total current liabilities			1,165,071				660,061
Commitments
Stockholders' equity:
	Common stock, $.0025 par value; authorized 50,000,000 shares; issued and outstanding: 20,871,772 shares				52,179				52,179
	Additional paid-in capital				21,364,686				21,313,319
	Accumulated deficit				(20,589,738	)			(20,134,773	)
					827,127				1,230,725
			Total liabilities and stockholders' equity	$	1,992,198			$	1,890,786